MediPharm Labs Sets Date to Report First Quarter 2025 Financial Results
MediPharm Labs (MEDIF), a pharmaceutical company focused on precision-based cannabinoids, has scheduled the release of its first quarter 2025 financial results for Wednesday, May 14, 2025, before markets open. The company will host a conference call and webcast on the same day at 10:00 a.m. Eastern time to discuss the financial results.
Investors can join via North America Toll-Free at (888) 330-2454 or International Toll at +1 (240) 789-2714 using Conference ID 4921762. A webcast replay will be available on the company's investor relations website approximately one day after the call.
MediPharm Labs (MEDIF), un'azienda farmaceutica specializzata in cannabinoidi basati sulla precisione, ha programmato la pubblicazione dei suoi risultati finanziari del primo trimestre 2025 per mercoledì 14 maggio 2025, prima dell'apertura dei mercati. La società terrà una conference call e una webcast lo stesso giorno alle 10:00 ora orientale per discutere i risultati finanziari.
Gli investitori potranno partecipare chiamando il numero gratuito per il Nord America (888) 330-2454 o il numero internazionale +1 (240) 789-2714 utilizzando il codice conferenza 4921762. Una replica della webcast sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda circa un giorno dopo la chiamata.
MediPharm Labs (MEDIF), una empresa farmacéutica centrada en cannabinoides de precisión, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el miércoles 14 de mayo de 2025, antes de la apertura de los mercados. La compañía realizará una llamada de conferencia y una transmisión en línea el mismo día a las 10:00 a.m., hora del este, para discutir los resultados financieros.
Los inversores pueden unirse llamando al número gratuito para Norteamérica (888) 330-2454 o al número internacional +1 (240) 789-2714 usando el ID de conferencia 4921762. Una repetición de la transmisión estará disponible en el sitio web de relaciones con inversores de la empresa aproximadamente un día después de la llamada.
MediPharm Labs (MEDIF)는 정밀 기반 칸나비노이드에 집중하는 제약회사로, 2025년 1분기 재무 결과를 2025년 5월 14일 수요일 시장 개장 전에 발표할 예정입니다. 회사는 같은 날 동부 시간 오전 10시에 재무 결과를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 진행합니다.
투자자들은 북미 무료 전화 (888) 330-2454 또는 국제 전화 +1 (240) 789-2714를 통해 회의 ID 4921762를 사용하여 참여할 수 있습니다. 웹캐스트 녹화는 통화 후 약 하루 뒤 회사 투자자 관계 웹사이트에서 제공될 예정입니다.
MediPharm Labs (MEDIF), une entreprise pharmaceutique spécialisée dans les cannabinoïdes de précision, a prévu la publication de ses résultats financiers du premier trimestre 2025 pour le mercredi 14 mai 2025, avant l'ouverture des marchés. La société organisera une conférence téléphonique et une webdiffusion le même jour à 10h00, heure de l'Est, pour discuter des résultats financiers.
Les investisseurs peuvent participer en appelant le numéro vert pour l'Amérique du Nord au (888) 330-2454 ou le numéro international au +1 (240) 789-2714 en utilisant l'ID de conférence 4921762. Une rediffusion de la webdiffusion sera disponible sur le site des relations investisseurs de l'entreprise environ un jour après l'appel.
MediPharm Labs (MEDIF), ein Pharmaunternehmen mit Fokus auf präzisionsbasierte Cannabinoide, hat die Veröffentlichung seiner Finanzergebnisse für das erste Quartal 2025 für Mittwoch, den 14. Mai 2025, vor Markteröffnung geplant. Das Unternehmen wird am selben Tag um 10:00 Uhr Eastern Time eine Telefonkonferenz und Webcast abhalten, um die Finanzergebnisse zu besprechen.
Investoren können über die gebührenfreie Nordamerika-Nummer (888) 330-2454 oder die internationale Nummer +1 (240) 789-2714 unter Verwendung der Konferenz-ID 4921762 teilnehmen. Eine Aufzeichnung des Webcasts wird etwa einen Tag nach dem Anruf auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
MediPharm Labs executive management team will also host a conference call and webcast on Wednesday, May 14, 2025, at 10:00 a.m. (Eastern time) to discuss the Company's financial results.
Conference Call Dial in Details:
North America Toll-Free: (888) 330-2454
International Toll: +1 (240) 789-2714
Conference ID: 4921762
Participants are asked to dial in approximately 15 minutes before the start of the call.
Webcast:
A webcast will be available by visiting the following link here.
For those who are unable to participate on the live conference call or webcast, a replay will be available at https://www.medipharmlabs.com/investors approximately one day after completion of the call.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA.
In 2023, MediPharm acquired VIVO Cannabis Inc. which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical PTY and Beacon Medical GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions.
The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
Website: www.medipharmlabs.com
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding the release of MediPharm's financial results and the future of MediPharm's foreign drug manufacturing site registration. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's filings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
View original content to download multimedia:https://www.prnewswire.com/news-releases/medipharm-labs-sets-date-to-report-first-quarter-2025-financial-results-302450783.html
SOURCE MediPharm Labs Corp.
FAQ
When will MediPharm Labs (MEDIF) release Q1 2025 earnings?
What time is MediPharm Labs' Q1 2025 earnings call?
How can I join MediPharm Labs' Q1 2025 earnings call?
Where can I find the replay of MediPharm Labs' Q1 2025 earnings call?
